Five-year survival in breast cancer treated with adjuvant immunotherapy
In this follow-up report of the treatment of primary breast cancer with adjuvant immunotherapy, a total of 95 patients were studied: 46 patients with stage I breast cancer and 49 patients with stage II breast cancer. All patients underwent standard surgical treatment and received immunotherapy as ad...
Gespeichert in:
| Veröffentlicht in: | The American journal of surgery 1994-07, Vol.168 (1), p.19-21 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 21 |
|---|---|
| container_issue | 1 |
| container_start_page | 19 |
| container_title | The American journal of surgery |
| container_volume | 168 |
| creator | Lytle, Glenn H. McGee, J. Michael Yamanashi, William S. Malnar, Karen Bellefeuille, Charlotte Humphrey, Loren J. |
| description | In this follow-up report of the treatment of primary breast cancer with adjuvant immunotherapy, a total of 95 patients were studied: 46 patients with stage I breast cancer and 49 patients with stage II breast cancer. All patients underwent standard surgical treatment and received immunotherapy as adjuvant treatment. Patients received a primary series of eight doses (1 mL of tumor-associated antigen preparation given as 0.2 mL intradermally and 0.8 mL subcutaneously) given over 8 weeks, and then booster injections every 3 months for at least 2 years. The 5-year survival with adjuvant immunotherapy was 83% for those with negative axillary nodes and 53% for those with positive nodes; this compares favorably with national 5-year survival statistics from two other studies (node-negative, 72% and 83%; node-positive, 51% and 59%). Based on these data, the addition of immunotherapy to other adjuvant therapies in randomized prospective trials seems both reasonable and justified. |
| doi_str_mv | 10.1016/S0002-9610(05)80064-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76573078</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002961005800649</els_id><sourcerecordid>2847440687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-d8c38b5f3304cb9eb3b6dfbde21934121d287265da004156e04216b3b9abf5533</originalsourceid><addsrcrecordid>eNqFkEtr3DAURkVpSCePnxAwFEqzcHNlPSyvSgiZaSGQRdq1kKVrosGPqSQ7zL-vkhmy6Kary8c998Eh5IrCNwpU3jwBQFU2ksJXENcKQPKy-UBWVNVNSZViH8nqHflEzmLc5kgpZ6fkVEHFoWErsln7Bcs9mlDEOSx-MX3hx6INaGIqrBkthiLllNAVLz49F8Zt58WMqfDDMI9TesZgdvsLctKZPuLlsZ6T3-v7X3c_yofHzc-724fSMmCpdMoy1YqOMeC2bbBlrXRd67CiDeO0oq5SdSWFMwCcConAKyoz1Zi2E4Kxc_LlsHcXpj8zxqQHHy32vRlxmqOupagZ1CqDn_8Bt9McxvybrhSvOQep6kyJA2XDFGPATu-CH0zYawr6VbN-06xfHWoQ-k2zbvLc1XH73A7o3qeOXnP_-6GP2cXiMehoPWaZzge0SbvJ_-fCX8GIi3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2847440687</pqid></control><display><type>article</type><title>Five-year survival in breast cancer treated with adjuvant immunotherapy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Lytle, Glenn H. ; McGee, J. Michael ; Yamanashi, William S. ; Malnar, Karen ; Bellefeuille, Charlotte ; Humphrey, Loren J.</creator><creatorcontrib>Lytle, Glenn H. ; McGee, J. Michael ; Yamanashi, William S. ; Malnar, Karen ; Bellefeuille, Charlotte ; Humphrey, Loren J.</creatorcontrib><description>In this follow-up report of the treatment of primary breast cancer with adjuvant immunotherapy, a total of 95 patients were studied: 46 patients with stage I breast cancer and 49 patients with stage II breast cancer. All patients underwent standard surgical treatment and received immunotherapy as adjuvant treatment. Patients received a primary series of eight doses (1 mL of tumor-associated antigen preparation given as 0.2 mL intradermally and 0.8 mL subcutaneously) given over 8 weeks, and then booster injections every 3 months for at least 2 years. The 5-year survival with adjuvant immunotherapy was 83% for those with negative axillary nodes and 53% for those with positive nodes; this compares favorably with national 5-year survival statistics from two other studies (node-negative, 72% and 83%; node-positive, 51% and 59%). Based on these data, the addition of immunotherapy to other adjuvant therapies in randomized prospective trials seems both reasonable and justified.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/S0002-9610(05)80064-9</identifier><identifier>PMID: 8024093</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Actuarial Analysis ; Adjuvants, Immunologic - therapeutic use ; Adult ; Age Distribution ; Aged ; Antigen (tumor-associated) ; Antigens ; Antigens, Neoplasm - immunology ; Antineoplastic Agents - therapeutic use ; Breast cancer ; Breast Neoplasms - immunology ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Case-Control Studies ; Chemotherapy, Adjuvant ; Clinical trials ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Immunization, Secondary ; Immunotherapy ; Injections, Intradermal ; Injections, Subcutaneous ; Middle Aged ; Neoplasm Staging ; Nodes ; Survival ; Survival Rate</subject><ispartof>The American journal of surgery, 1994-07, Vol.168 (1), p.19-21</ispartof><rights>1994 Reed Publishing USA</rights><rights>1994. Reed Publishing USA</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c303t-d8c38b5f3304cb9eb3b6dfbde21934121d287265da004156e04216b3b9abf5533</citedby><cites>FETCH-LOGICAL-c303t-d8c38b5f3304cb9eb3b6dfbde21934121d287265da004156e04216b3b9abf5533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2847440687?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994,64384,64386,64388,72340</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8024093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lytle, Glenn H.</creatorcontrib><creatorcontrib>McGee, J. Michael</creatorcontrib><creatorcontrib>Yamanashi, William S.</creatorcontrib><creatorcontrib>Malnar, Karen</creatorcontrib><creatorcontrib>Bellefeuille, Charlotte</creatorcontrib><creatorcontrib>Humphrey, Loren J.</creatorcontrib><title>Five-year survival in breast cancer treated with adjuvant immunotherapy</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>In this follow-up report of the treatment of primary breast cancer with adjuvant immunotherapy, a total of 95 patients were studied: 46 patients with stage I breast cancer and 49 patients with stage II breast cancer. All patients underwent standard surgical treatment and received immunotherapy as adjuvant treatment. Patients received a primary series of eight doses (1 mL of tumor-associated antigen preparation given as 0.2 mL intradermally and 0.8 mL subcutaneously) given over 8 weeks, and then booster injections every 3 months for at least 2 years. The 5-year survival with adjuvant immunotherapy was 83% for those with negative axillary nodes and 53% for those with positive nodes; this compares favorably with national 5-year survival statistics from two other studies (node-negative, 72% and 83%; node-positive, 51% and 59%). Based on these data, the addition of immunotherapy to other adjuvant therapies in randomized prospective trials seems both reasonable and justified.</description><subject>Actuarial Analysis</subject><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Adult</subject><subject>Age Distribution</subject><subject>Aged</subject><subject>Antigen (tumor-associated)</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Case-Control Studies</subject><subject>Chemotherapy, Adjuvant</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunization, Secondary</subject><subject>Immunotherapy</subject><subject>Injections, Intradermal</subject><subject>Injections, Subcutaneous</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Nodes</subject><subject>Survival</subject><subject>Survival Rate</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkEtr3DAURkVpSCePnxAwFEqzcHNlPSyvSgiZaSGQRdq1kKVrosGPqSQ7zL-vkhmy6Kary8c998Eh5IrCNwpU3jwBQFU2ksJXENcKQPKy-UBWVNVNSZViH8nqHflEzmLc5kgpZ6fkVEHFoWErsln7Bcs9mlDEOSx-MX3hx6INaGIqrBkthiLllNAVLz49F8Zt58WMqfDDMI9TesZgdvsLctKZPuLlsZ6T3-v7X3c_yofHzc-724fSMmCpdMoy1YqOMeC2bbBlrXRd67CiDeO0oq5SdSWFMwCcConAKyoz1Zi2E4Kxc_LlsHcXpj8zxqQHHy32vRlxmqOupagZ1CqDn_8Bt9McxvybrhSvOQep6kyJA2XDFGPATu-CH0zYawr6VbN-06xfHWoQ-k2zbvLc1XH73A7o3qeOXnP_-6GP2cXiMehoPWaZzge0SbvJ_-fCX8GIi3g</recordid><startdate>199407</startdate><enddate>199407</enddate><creator>Lytle, Glenn H.</creator><creator>McGee, J. Michael</creator><creator>Yamanashi, William S.</creator><creator>Malnar, Karen</creator><creator>Bellefeuille, Charlotte</creator><creator>Humphrey, Loren J.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>199407</creationdate><title>Five-year survival in breast cancer treated with adjuvant immunotherapy</title><author>Lytle, Glenn H. ; McGee, J. Michael ; Yamanashi, William S. ; Malnar, Karen ; Bellefeuille, Charlotte ; Humphrey, Loren J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-d8c38b5f3304cb9eb3b6dfbde21934121d287265da004156e04216b3b9abf5533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Actuarial Analysis</topic><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Adult</topic><topic>Age Distribution</topic><topic>Aged</topic><topic>Antigen (tumor-associated)</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Case-Control Studies</topic><topic>Chemotherapy, Adjuvant</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunization, Secondary</topic><topic>Immunotherapy</topic><topic>Injections, Intradermal</topic><topic>Injections, Subcutaneous</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Nodes</topic><topic>Survival</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lytle, Glenn H.</creatorcontrib><creatorcontrib>McGee, J. Michael</creatorcontrib><creatorcontrib>Yamanashi, William S.</creatorcontrib><creatorcontrib>Malnar, Karen</creatorcontrib><creatorcontrib>Bellefeuille, Charlotte</creatorcontrib><creatorcontrib>Humphrey, Loren J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lytle, Glenn H.</au><au>McGee, J. Michael</au><au>Yamanashi, William S.</au><au>Malnar, Karen</au><au>Bellefeuille, Charlotte</au><au>Humphrey, Loren J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Five-year survival in breast cancer treated with adjuvant immunotherapy</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>1994-07</date><risdate>1994</risdate><volume>168</volume><issue>1</issue><spage>19</spage><epage>21</epage><pages>19-21</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>In this follow-up report of the treatment of primary breast cancer with adjuvant immunotherapy, a total of 95 patients were studied: 46 patients with stage I breast cancer and 49 patients with stage II breast cancer. All patients underwent standard surgical treatment and received immunotherapy as adjuvant treatment. Patients received a primary series of eight doses (1 mL of tumor-associated antigen preparation given as 0.2 mL intradermally and 0.8 mL subcutaneously) given over 8 weeks, and then booster injections every 3 months for at least 2 years. The 5-year survival with adjuvant immunotherapy was 83% for those with negative axillary nodes and 53% for those with positive nodes; this compares favorably with national 5-year survival statistics from two other studies (node-negative, 72% and 83%; node-positive, 51% and 59%). Based on these data, the addition of immunotherapy to other adjuvant therapies in randomized prospective trials seems both reasonable and justified.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>8024093</pmid><doi>10.1016/S0002-9610(05)80064-9</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9610 |
| ispartof | The American journal of surgery, 1994-07, Vol.168 (1), p.19-21 |
| issn | 0002-9610 1879-1883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76573078 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Actuarial Analysis Adjuvants, Immunologic - therapeutic use Adult Age Distribution Aged Antigen (tumor-associated) Antigens Antigens, Neoplasm - immunology Antineoplastic Agents - therapeutic use Breast cancer Breast Neoplasms - immunology Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - surgery Case-Control Studies Chemotherapy, Adjuvant Clinical trials Combined Modality Therapy Female Follow-Up Studies Humans Immunization, Secondary Immunotherapy Injections, Intradermal Injections, Subcutaneous Middle Aged Neoplasm Staging Nodes Survival Survival Rate |
| title | Five-year survival in breast cancer treated with adjuvant immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A48%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Five-year%20survival%20in%20breast%20cancer%20treated%20with%20adjuvant%20immunotherapy&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Lytle,%20Glenn%20H.&rft.date=1994-07&rft.volume=168&rft.issue=1&rft.spage=19&rft.epage=21&rft.pages=19-21&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/S0002-9610(05)80064-9&rft_dat=%3Cproquest_cross%3E2847440687%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2847440687&rft_id=info:pmid/8024093&rft_els_id=S0002961005800649&rfr_iscdi=true |